Default company panoramic image

LaZure Scientific, Inc.

LaZure is developing a promising CaP treatment that preferentially destroys cancer cells while leaving healthy tissue and nerves unharmed.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Issaquah, WA, USA
  • Currency USD
  • Founded December 2006
  • Employees 3
  • Website

Company Summary

Conventional cancer therapies include a host of unwanted side effects that dramatically impact quality of life after treatment, whether the treatment is successful or not. LaZure Scientific has developed a cancer treatment technology that preferentially destroys cancer cells while leaving healthy tissue, such as nerves and blood vessels, unharmed. The preferential nature of the treatment results in a reduction of treatment related side-effects.


  • Default avatar
    Charles HIll
    President and CEO

    Mr. Hill brings over 20 years of business and executive management experience, Since 2006 Mr. Hill has guided LaZure Scientific, Inc. from an idea, through the pre-clinical stage, and now into human clinical trials. Prior to LaZure, Mr. Hill spent ten years with Pistol Creek Company, a large, privately held investment company, ultimately achieving the position of President and CEO. At Pistol Creek, Mr. Hill provided leadership in all areas of o

  • Default avatar
    Paul Lange, MD

    Dr. Lange graduated from Washington University Medical School and received his general surgery and urology training at the University of Rochester, Duke University and the University of Minnesota. In 1988, Dr. Lange moved to the University of Washington as Professor and Chairman of the Department of Urology. He remained at that position for 19 years and then stepped down to become Director of the Institute for Prostate Cancer Research, a multid

  • Default avatar
    Andrew Azure
    Vice President

    Mr. Andrew Azure brings over 20 years of marketing, operations and general management experience to his role as Vice President. Prior to the founding of LaZure, Mr. Azure was the Vice President and General Manager of Rejuvenetics where he oversaw all areas of day-to-day operations. Prior to Rejuvenetics, Mr. Azure held the position of VP/General Manager for Best Use Corporation, a surplus medical equipment remarketer. Mr. Azure was also part o

  • Default avatar
    Joshua Hockett
    Chief Technical Officer

    Joshua brings over 8 years of engineering and system design experience to LaZure Scientific. Since joining the company in April 2010, Joshua has led, as the chief system architect, the engineering and development of the LaZure LDAC system currently in use in human clinical trials. Joshua previously held the position of Program Manager at Synapse Product Development, a contract engineering and design firm, where he lead multi-disciplinary design